Research programme: hypoxia-inducible factor-1 alpha inhibitors - Ocuphire Pharma
Alternative Names: RX-0047; RX-0047 nanoliposomal; RX-0047-N; RX-0047-NanoLatest Information Update: 13 Nov 2020
At a glance
- Originator Rexahn Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Hypoxia-inducible factor 1 alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 05 Nov 2020 Rexahn Pharmaceuticals has been merged with Ocuphire Pharma to form Ocuphire Pharma
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 21 Dec 2010 Preclinical development is ongoing for RX 0047 N